BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schittenhelm J, Simon P, Harter PN, Zachskorn C, Schlaszus H, Röttger F, Winkels M, Weller M, Meyermann R, Mittelbronn M. CD133 expression is associated with small round blue cell tumour morphology in human central nervous system neoplasms: CD133 in CNS neoplasms. Histopathology 2011;58:739-49. [DOI: 10.1111/j.1365-2559.2011.03801.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Niyazi M, Harter PN, Hattingen E, Rottler M, von Baumgarten L, Proescholdt M, Belka C, Lauber K, Mittelbronn M. Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance? Oncotarget 2016;7:2313-28. [PMID: 26575171 DOI: 10.18632/oncotarget.6320] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
2 Jelen S, Parm Ulhøi B, Larsen A, Frøkiær J, Nielsen S, Rützler M. AQP9 expression in glioblastoma multiforme tumors is limited to a small population of astrocytic cells and CD15(+)/CalB(+) leukocytes. PLoS One 2013;8:e75764. [PMID: 24086629 DOI: 10.1371/journal.pone.0075764] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
3 Sartelet H, Imbriglio T, Nyalendo C, Haddad E, Annabi B, Duval M, Fetni R, Victor K, Alexendrov L, Sinnett D, Fabre M, Vassal G. CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway: CD133 in neuroblastoma. Histopathology 2012;60:1144-55. [DOI: 10.1111/j.1365-2559.2012.04191.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 4.6] [Reference Citation Analysis]